|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:approvalYear
|
2013
|
|
gptkbp:ATCCode
|
gptkb:J05AP08
|
|
gptkbp:bioavailability
|
~92%
|
|
gptkbp:blackBoxWarning
|
risk of hepatitis B reactivation
|
|
gptkbp:CASNumber
|
1190307-88-0
|
|
gptkbp:contraindication
|
coadministration with amiodarone
|
|
gptkbp:drugClass
|
antiviral
nucleotide
|
|
gptkbp:eliminatedIn
|
renal
|
|
gptkbp:eliminationHalfLife
|
0.4 hours (sofosbuvir), 27 hours (GS-331007)
|
|
gptkbp:excretion
|
gptkb:kidney
|
|
gptkbp:hasInChIKey
|
YYEJJZCTQZJYQB-AATRIKPKSA-N
|
|
gptkbp:hasMetabolite
|
gptkb:GS-331007
|
|
gptkbp:hasMolecularFormula
|
C22H29FN3O9P
|
|
gptkbp:hasPatentExpiry
|
2029 (US)
|
|
gptkbp:hasPatentHolder
|
gptkb:Gilead_Sciences
|
|
gptkbp:hasSMILES
|
CC(C)COC(=O)[C@H](NC(=O)[C@H](N)C(C)C)P(=O)(O)O
|
|
gptkbp:hasUNII
|
Q1Q1XK97B3
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
DB09223
|
|
gptkbp:indication
|
treatment of hepatitis C
|
|
gptkbp:isApprovedDrug
|
true
|
|
gptkbp:isUsedInCombinationWith
|
gptkb:daclatasvir
ledipasvir
velpatasvir
|
|
gptkbp:KEGGID
|
gptkb:D10366
|
|
gptkbp:legalStatus
|
prescription only
Rx-only
|
|
gptkbp:manufacturer
|
gptkb:Gilead_Sciences
|
|
gptkbp:mechanismOfAction
|
NS5B RNA-dependent RNA polymerase inhibitor
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:molecularWeight
|
529.45 g/mol
|
|
gptkbp:name
|
gptkb:Sofosbuvir
|
|
gptkbp:pregnancyCategory
|
B1 (Australia)
B1 (AU), not assigned (US)
|
|
gptkbp:proteinBinding
|
61-65%
|
|
gptkbp:PubChem_CID
|
gptkb:DB09223
gptkb:CHEMBL1259058
45375808
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
gptkb:anemia
nausea
fatigue
headache
insomnia
|
|
gptkbp:synonym
|
gptkb:Sovaldi
gptkb:GS-7977
gptkb:PSI-7977
|
|
gptkbp:target
|
NS5B polymerase
|
|
gptkbp:therapeuticArea
|
gptkb:disease
hepatology
|
|
gptkbp:bfsParent
|
gptkb:plastic
|
|
gptkbp:bfsLayer
|
4
|